GlassScriptPhysician profile
Ethan Routt
NPI 1194112391
$3,013.55
in general payments reported to CMS, 2019-2025
22 companies · $733 in 2025
The $733 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $75.00 · 2021: $309 · 2022: $500 · 2023: $692 · 2024: $595 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002 · Education: $18.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.57 |
| Education | $18.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $927.04 | 2021-2025 | Rinvoq, Skyrizi, Humira |
| Regeneron Healthcare Solutions, INC. | $630.74 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $268.15 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $171.21 | 2021-2025 | |
| Incyte Corporation | $155.84 | 2022-2024 | Opzelura |
| Pfizer INC. | $105.06 | 2023-2025 | |
| Ucb, INC. | $99.74 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $85.41 | 2021-2025 | Simponi Aria, Simponi, Stelara |
| E.R. Squibb & Sons, L.L.C. | $76.90 | 2024-2025 | Sotyktu |
| Prugen, INC. Pharmaceuticals | $75.00 | 2020 | |
| Celgene Corporation | $65.10 | 2019 | |
| Galderma Laboratories, L.P. | $51.08 | 2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $45.24 | 2024 | Adbry |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Sun Pharmaceutical Industries INC. | $40.87 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.89 | 2023 | |
| Arcutis Biotherapeutics, INC. | $24.83 | 2024 | Zoryve |
| Sanofi-Aventis U.S. LLC | $24.64 | 2021 | |
| Smith+Nephew, INC. | $24.26 | 2024 | Grafix Pl |
| Dermavant Sciences, INC. | $24.11 | 2023 | Vtama |
| Revance Therapeutics, INC. | $21.85 | 2024 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.59 | 2024 | Arazlo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Routt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.